{"entity":{"id":"tg4050","kind":"drug","name":"TG4050","aka":[],"tldr":"TG4050 is an experimental individualised neoantigen therapeutic vaccine from Transgene, in phase 2 trials for HPV-negative head and neck squamous cell carcinoma and ovarian cancer.","summary":"TG4050 is an individualised neoantigen therapeutic vaccine (myvac platform) from Transgene. The lead individualised neoantigen therapeutic vaccine from Transgene's myvac platform, given as a single agent after surgery. Its furthest stage is phase 2, for HPV-negative head and neck squamous cell carcinoma (adjuvant) and ovarian cancer. ClinicalTrials.gov registers it in 2 studies linked below. Transgene: randomised multicentre phase 2 part of a phase 1/2 trial (NCT04183166, active, not recruiting). An ovarian cancer phase 1 (NCT03839524) is completed. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Transgene: transgene.com","url":"https://www.transgene.com/tg4050/"},{"label":"ClinicalTrials.gov: trials of TG4050","url":"https://clinicaltrials.gov/search?intr=TG4050"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hpv-negative-head-and-neck-cancer","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["transgene"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04183166","nct03839524"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"TG4050","modality":"Individualised neoantigen therapeutic vaccine (myvac platform)","mechanism":"The lead individualised neoantigen therapeutic vaccine from Transgene's myvac platform, given as a single agent after surgery.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tg4050/","neighbours":{"cancer":[{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/"}],"trial":[{"id":"nct04183166","kind":"trial","name":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","route":"/trials/nct04183166/"},{"id":"nct03839524","kind":"trial","name":"A Trial Evaluating TG4050 in Ovarian Carcinoma.","route":"/trials/nct03839524/"}]}}